Brain Cancer Trial, Recruiting NCT07552233 Sponsor: Peking University Third Hospital Condition: Brain Cancer
Back to Brain Cancer

Brain Cancer Trial, Recruiting

NCT07552233
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People aged 18 to 70 years old (inclusive), of any gender
  • People who have at least one tumour that can be assessed, with a confirmed diagnosis of a malignant brain or central nervous system tumour, and imaging showing the tumour has continued to grow or come back after treatment
  • People whose general physical functioning scores at least 60% on a standard medical performance scale, meaning they are able to care for themselves and are up and about more than half the time (confirm with trial site)
  • People with a life expectancy of more than 4 weeks who are able to have an MRI scan with contrast dye
  • People who finished radiotherapy or other systemic treatments (such as temozolomide, bevacizumab, or other medicines) at least 4 weeks before joining, and whose side effects from those treatments have mostly resolved to a mild or minimal level
  • People taking no more than 4 mg per day of dexamethasone (a type of steroid), or an equivalent low dose of a similar medicine, or none at all
  • People whose blood test results show that the bone marrow, liver, kidneys, and other organs are functioning adequately (the trial site will check specific blood values)
  • People with no known hereditary diseases
  • People with normal heart function, where the heart is pumping at more than 55% of its capacity
  • People with no bleeding or blood clotting disorders
  • People who have no sign of active bacterial, fungal, or viral infection in the blood, and no signs of meningitis (brain/spinal cord membrane infection), within 48 hours before receiving the treatment cells
  • Women who could become pregnant must have had a negative pregnancy test within 7 days before starting treatment, and must be willing to use contraception during the trial and for 6 months after the last treatment session
  • People who have read, understood, and signed the informed consent form

Who may not be able to join:

  • People with active hepatitis B, hepatitis C, HIV infection, or any other untreated active infection
  • People who are pregnant or breastfeeding
  • People with organ failure
  • People with a long-term (chronic) condition that requires ongoing immune-suppressing or hormonal treatment
  • People with a known allergy to immunotherapy or the types of cells used in this treatment
  • People with another serious illness that is not under control
  • People with a psychiatric illness or personal circumstances that would make it difficult to follow the trial requirements
  • People who have previously had an organ transplant or who are currently waiting for one

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 14 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: (+86)-135-1108-7060

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Peking University Third Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 December 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Incidence of Adverse Events (AEs); Incidence of Dose-Limiting Toxicities (DLTs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 14 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov